Most Read Articles
Elaine Soliven, 27 Sep 2017
A second dose of kisspeptin-54 improves oocyte yield in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) treatment, according to a recent study.
23 Oct 2017
Pearl Toh spoke with Dr Teh Ming Ming, senior consultant at the Department of Endocrinology, Singapore General Hospital (SGH), on the major challenges of diagnosing and managing diabetes in primary care, in conjunction with the World Diabetes Day on 14 November. Awareness of the symptoms of diabetes is important, and patients should be empowered to manage their conditions.
Rachel Soon, Yesterday

Pharmacists can and should utilize their positions within communities to provide access to an extended range of healthcare services, says an expert.

01 Aug 2017
New drug applications approved by US FDA as of 1 - 15 June 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

TNFi, corticosteroids up risk of herpes zoster in patients with RA

12 Jul 2017

The use of tumour necrosis factor inhibitor (TNFi) and higher dosage of corticosteroids appear to increase the incidence of herpes zoster in patients with rheumatoid arthritis (RA) in the clinical setting, according to a Japan study.

Researchers measured the crude incidence rate (IR) of herpes zoster treated with systemic antiviral medications in 1987 patients (median age 60.0 years; 81.5 percent female) from the Registry of Japanese Rheumatoid Arthritis Patients on Biologics for Longterm Safety (REAL) database.

To investigate the association between herpes zoster and medications, the authors performed a nested case–control study with 1:5 case-control pairs matched for age, sex, observation start year and comorbidity (herpes zoster group, n=43; control group, n=214).

A conditional logistic regression analysis was performed to calculate the odds ratio (OR) and 95 percent CI of the use of biological disease-modifying antirheumatic drugs (bDMARD), methotrexate (MTX) and corticosteroids for the occurrence of herpes zoster.

The median disease duration among participants was 6.0 years, and the crude IR of herpes zoster was 6.66 (95 percent CI, 4.92 to 8.83) per 1,000 person-years.

The ORs of medication use were 2.28 (1.09 to 4.76) for TNFi and 1.13 (1.03 to 1.23) for oral corticosteroid dosage (per 1 mg prednisolone increment), both of which were significantly increased. There were no increases in the ORs of non-TNFi and MTX usage.

These findings support the results of another study, which found that patients with RA taking specific immunosuppressive medication had an elevated risk of herpes zoster. Biologicals used correlated with severe herpes zoster occurrence. Researchers suggested the close monitoring and prevention of severe herpes zoster during specific immunosuppressive therapy. [BMJ Open 2017;7:e014032]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Elaine Soliven, 27 Sep 2017
A second dose of kisspeptin-54 improves oocyte yield in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) treatment, according to a recent study.
23 Oct 2017
Pearl Toh spoke with Dr Teh Ming Ming, senior consultant at the Department of Endocrinology, Singapore General Hospital (SGH), on the major challenges of diagnosing and managing diabetes in primary care, in conjunction with the World Diabetes Day on 14 November. Awareness of the symptoms of diabetes is important, and patients should be empowered to manage their conditions.
Rachel Soon, Yesterday

Pharmacists can and should utilize their positions within communities to provide access to an extended range of healthcare services, says an expert.

01 Aug 2017
New drug applications approved by US FDA as of 1 - 15 June 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.